Jonathan Meyer
Psychiatry · San Diego, CANPI 1003832809
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,618,722 of the $2,326,979 with a category attached, or 69.6%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.0%. 2025 is the largest year on record at $651,650, 2.8 times the $232,344 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,192 payments — averaging $1061.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$490K
- Teva Pharmaceuticals USA, Inc.$382K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371K
- Neurocrine Biosciences, Inc.$363K
- AbbVie$180K
- E.r. Squibb & Sons, L.L.C.$165K
- plus $377K from 17 others
What the payments were for
- Consulting fees$494,14821%
- Speaking & faculty fees$1,618,72270%
- Travel & lodging$160,9647%
- Food & beverage$53,0382%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 477 | $489,755 |
| Teva Pharmaceuticals USA, Inc. | 303 | $382,172 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 369 | $370,732 |
| Neurocrine Biosciences, Inc. | 321 | $362,880 |
| AbbVie(2 entities) | 204 | $180,124 |
| E.r. Squibb & Sons, L.L.C. | 128 | $164,697 |
| Axsome Therapeutics, Inc. | 126 | $147,245 |
| Sunovion Pharmaceuticals Inc. | 105 | $95,370 |
| Acadia Pharmaceuticals Inc | 73 | $73,689 |
| Otsuka America Pharmaceutical, Inc. | 27 | $20,257 |
| Noven Pharmaceuticals, Inc. | 13 | $13,276 |
| Luye Pharma (USA) Ltd. | 6 | $9,900 |
| Johnson & Johnson | 15 | $5,248 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $4,753 |
| Sumitomo Pharma America, Inc. | 1 | $3,655 |
| Janssen Scientific Affairs, LLC | 1 | $2,778 |
| Tris Pharma Inc | 3 | $145 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $85 |
| Supernus Pharmaceuticals, Inc. | 2 | $84 |
| Shire North American Group Inc | 2 | $43 |
| Biogen | 1 | $36 |
| Boehringer Ingelheim | 1 | $36 |
| Abbott | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$949,210
- ARISTADA$904,306
- CAPLYTA$365,517
- INGREZZA$349,501
- UZEDY$280,899
- ARISTADA INITIO$215,852
- VRAYLAR$148,061
- Auvelity$145,090
- COBENFY$108,180
- LATUDA$89,145
- NUPLAZID$68,410
- Austedo XR$54,354
- REXULTI$19,836
- Elahere$18,160
- SECUADO$13,276
- ERZOFRI EXTENDED-RELEASE$9,900
- AUSTEDO$8,450
- SPRAVATO$4,914
- DISEASE EDUCATION$1,250
How this compares
$2,326,979 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Diego
- Sanjai RaoSan Diego$445K
- Murray SteinSan Diego$121K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.